Skip to main content
Equibles
LENZ logo

LENZ · LENZ Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track LENZ — free

Use LENZ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LENZ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.79 -0.05 (-1.30%) At close · Oct 1
Russell 2000 member Rebalance outlook locked
Market Cap
$123.01M
Shares
31.42M
Volume · Oct 1 738.9K Avg daily vol (3M) 855.44K

LENZ Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for LENZ Therapeutics, Inc. (LENZ), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$10.25M '24 Q2 24-08-14 · $ −$10.21M '24 Q3 24-11-06 · $ −$14.62M '25 Q1 25-05-07 · $12.50M −$16.70M '25 Q3 25-11-05 · $1.59M −$35.90M '25 Q4 26-03-24 · $1.90M −$41.49M '26 Q1 26-05-11 LATEST ▲9.7% $5.49M −$31.92M '26 Q2 26-08-11
Earnings call
FY26 · Q2
2026-08-11
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
Positive tone Telehealth access initiative Patient persistence and refills July launch momentum
Revenue
$5.49M
▲ 9.7% YoY
Diluted EPS
$-1.02
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
Positive tone Real-world efficacy and prescriber experience Launch adoption pacing R&D spending going to zero
Revenue
$1.90M
Diluted EPS
$-1.32
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Confident tone Launch traction and prescriber base Direct-to-consumer campaign Patient persistence and refills
Revenue
$1.59M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript
Confident tone VIZZ commercial launch and early prescription uptake Distance vision benefit and potential label expansion Sales force deployment and optometry/ophthalmology targeting
Revenue
$12.50M
Diluted EPS
$-0.59
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript
Confident tone Commercial readiness and launch pillars Patient/DTC awareness and sampling LNZ100 regulatory progress and PDUFA
Revenue
$
Diluted EPS
$-0.53
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-19
LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
Confident tone LNZ100 regulatory progress and PDUFA timeline Commercial preparation and market opportunity Competitive positioning versus pilocarpine/VUITY
Revenue
$
Diluted EPS
$-0.38
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript
Confident tone NDA submission and FDA regulatory pathway Phase 3 CLARITY trial results for LNZ100 Use patterns among eye care professionals
Revenue
$
Diluted EPS
$-0.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript
Confident tone CLARITY Phase 3 trial results for LNZ100 Discontinuation and patient interest survey results NDA submission and regulatory pathway
Diluted EPS
$-3.53
Audio Transcript Slides 8-K10-Q
Showing 1–9 of 9 webcasts
Key facts CIK 1815776 CUSIP 52635N103 13F (30d) 5 filings 4 filers Visit website Investor relations